fda

Ignite It
3 min read • June 26, 2018

420 Investor: Cannabis Drug Approval Creates ‘Logic Issue’ For The US Government

Ignite It
2 min read • June 25, 2018

GW Pharma’s Epidiolex Becomes First Cannabis-Based FDA-Approved Drug

Ignite It
1 min read • June 25, 2018

‘FDA sends pre-emptive warning to anyone trying to peddle unapproved uses of medical marijuana or cannabidiol, now that $GWPH approved @SGottliebFDA statement’-STAT’s Adam Feuerstein Tweets

Ignite It
1 min read • April 26, 2018

INSYS Therapeutics Reports Collaboration With University Of California San Diego Center For Medicinal Cannabis Research

Ignite It
1 min read • April 19, 2018

FDA Panel Unanimously Votes To Say Benefits Of Co.’s Cannabis-Derived Treatment For Severe Childhood Epilepsy Outweigh Its Risks

Ignite It
5 min read • January 25, 2018

Why GW Pharma’s Epidiolex Results Could Shape The Future Of Cannabis-Based Therapeutics

Ignite It
1 min read • December 19, 2017

INSYS Therapeutics Reports Initiation Of Phase 2 Trial Of CBD Oral Solution For Treatment Of Refractory Childhood Absence Epilepsy In Pediatric Patients

Ignite It
4 min read • March 14, 2017

Trump, Sessions, Spicer And Medical Marijuana: Industry Insiders Discuss The Future Of Cannabis

Ignite It
3 min read • March 3, 2017

What A Federal Crackdown Could Mean For The First Public Marijuana REIT

Ignite It
1 min read • February 23, 2017

GW Pharma’s Steve Schultz Tells Benzinga Spicer’s Comments On DOJ Taking Action On States That Have Legalized Recreational Marijuana ‘Will Not Affect’ The Company ‘At All’

Ignite It
6 min read • January 10, 2017

Top Cannabis Industry Experts Share 17 Predictions For Marijuana Markets In 2017 – Part 1

Ignite It
2 min read • January 6, 2016

Zynerba Pharmaceuticals Reports Positive Initial Results From ZYN002 CBD Gel Phase 1 Single Rising Dose Trial and Initiation of Phase 1 Multiple Rising Dose Trial

Browse By Channels

 After-Hours Center
 Analyst Color
 Analyst Ratings
 Andy Barr
 Asia
 Asset Sales
 Be Your Own Boss
 Binary Options
 Biotech
 Bonds
 Broad U.S. Equity ETFs
 Buybacks
 california cannabis
 Cannabis
 cannabis earnings
 cannabis farms
 cannabis study
 Christopher Dillis
 CNBC
 Commodities
 Congress cannabis
 Congress hemp
 Contracts
 Crowdsourcing
 Cryptocurrency
 Currency ETFs
 Dividends
 Downgrades
 Earnings
 Earnings Beats
 Earnings Misses
 Econ #s
 Economics
 Education
 Emerging Market ETFs
 Emerging Markets
 Entertainment
 Entrepreneurship
 Equities
 ESG
 ETFs
 Eurozone
 Events
 Exclusives
 Fast Money
 FDA
 Federal Reserve
 Financial Advisors
 Financing
 Fintech
 first quarter earnings
 Forex
 Futures
 Gaming
 General
 Global
 Government
 Guidance
 Health Care
 Hedge Funds
 hemp bill
 hemp legalization
 hemp regulation
 Hot
 illegal cannabis farms
 Initiation
 Insider Trades
 Insurance
 Interview
 intoxicating hemp-derived products
 Intraday Update
 IPOs
 James Comer
 Large Cap
 Latin America
 Legal
 Long Ideas
 M&A
 Macro Economic Events
 Macro Notification
 Management
 marijuana
 Market Summary
 Market-Moving Exclusives
 Markets
 Media
 Mid Cap
 Movers
 Movers & Shakers
 New ETFs
 News
 Offerings
 Opinion
 Options
 Penny Stocks
 Personal Finance
 Politics
 Pre-Market Outlook
 Press Releases
 Previews
 Price Target
 Psychedelics
 Psychology
 Real Estate
 Regulations
 REIT
 Reiteration
 Rescheduling
 Restaurants
 Retail Sales
 Reviews
 Rumors
 SEC
 Sector ETFs
 Short Ideas
 Short Sellers
 Signals
 Small Business
 Small Cap
 Small Cap Analysis
 Social Media
 Specialty ETFs
 Sports
 Sports Betting
 Startups
 Stock Split
 Success Stories
 Taxes
 Tech
 Technicals
 THC
 Top Stories
 Topics
 Trading Ideas
 Travel
 UC Berkeley Cannabis Research Center
 unlicensed cannabis
 Upgrades
 WIIM

Join the Cannabis Revolution

Ready to access the most aggressive cannabis intelligence platform? Get started with IGNITE IT today.